Novo Nordisk Leans on Buyback and Implant Deal as Price Wars Threaten Margins
Published on 07/08/2026 at 09:09 | Redaktion boerse-global.de
Novo Nordisk is throwing up a double defense against a perfect storm of competitive pressure and regulatory price caps. The Danish pharma giant has been aggressively repurchasing its own stock — spending roughly 6.2 billion Danish kronen to cancel more than 23 million B-shares since February — while simultaneously forging a new partnership to develop a long-acting semaglutide implant. Yet behind these moves, the company’s CEO has warned of a profits slide of up to 13% this year, driven by sweeping discounts that investors fear will erode the core business.
The buyback programme, which has already consumed around 41% of a total 15 billion kronen commitment running until early 2027, now brings Novo Nordisk’s treasury stake to 0.9% of share capital. That technical support has helped steady the stock after a prolonged downturn, but the fundamentals remain under siege. The company lost its crown in the obesity-drug market to Eli Lilly, and clinical setbacks along with weak sales figures have weighed on sentiment. Chief executive Maziar Mike Doustdar acknowledged in February that deep price cuts are coming: from January 2027, Wegovy will be roughly halved in price, while Ozempic will become 35% cheaper. Those moves are part of a broader US pricing overhaul — a Medicare bridging programme that started on 1 July 2026 caps state-paid prices at $245 per monthly prescription and limits senior copayments to $50.
Against that backdrop, Novo Nordisk is trying to reinvigorate its pipeline. Its most advanced hope is Amycretin, a dual GLP-1 and amylin mimetic now in Phase 3 trials in both injectable and tablet forms. A separate bet has now been placed with Vivani Medical: the two companies will jointly test the NPM-139 semaglutide implant, designed to deliver a steady dose once or twice a year. The Phase 1 study is slated to begin in mid-2026 and will compare the implant head-to-head with the existing Wegovy injection.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The share price has recently shown some technical strength. In Copenhagen, the stock closed at 327.70 kroner on Monday after HSBC lifted its target from 280 to 300 kroner, though the bank maintained a neutral rating. On the Frankfurt exchange, the equity ended Tuesday at €43.43, a gain of roughly 22% over the past month, yet still down about 27% year-to-date. The Relative Strength Index now sits at 68.9, flashing an overbought signal, while the stock trades above both its 50-day and 200-day moving averages.
Analyst sentiment has turned cautious. Several firms downgraded the stock to “hold” in early July, and prominent investor Terry Smith sold his entire stake, calling Novo Nordisk an “investment disaster.” The next major catalyst arrives on 5 August 2026, when the company reports its quarterly results. Investors will be looking for evidence that the new Wegovy pill — which captured 65% of all new US prescriptions in the prior quarter — can offset the coming revenue squeeze from forced price reductions. Without operational progress in the diabetes and obesity franchise, the current buyback-driven stabilisation may prove only a temporary floor.
Ad
Novo Nordisk Stock: New Analysis - 8 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
